SEC Form 4 · accession 0001093557-18-000056
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew K Balo
Officer — EVP, Reg. Strategy, Clinical
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 9:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 12, 2018 | D | 2,834 | $60.7306 | D | 115,252 | D | |
| Common StockF1,F2 | Mar 12, 2018 | D | 2,221 | $60.7306 | D | 113,031 | D | |
| Common StockF1,F2 | Mar 12, 2018 | D | 4,464 | $60.7306 | D | 108,567 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.
- F2Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.